



ASX ANNOUNCEMENT

Invitation to Investor Information Session in Sydney on 2 April 2025

MELBOURNE, Australia (24 March 2025) – Lumos Diagnostics Holdings Ltd (ASX: LDX, “Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, is pleased to invite investors to attend an in-person information session to provide a business update, in Sydney on 2 April at 12.00pm.

Details for investor information session:

Time: Wednesday, 2 April 2025 at 12.00pm

Hosts: Doug Ward, Managing Director & CEO, and Barrie Lambert, CFO

Location: Bond Business Centre, Midnight Rambler Room, Workspace 365
20 Bond Street, Sydney NSW
Take lift to Level 5, visit reception area, and follow directions for the Level 4 room (downstairs or via internal lift)

Refreshments: A light lunch, tea and coffee will be available during the presentation.

To register your interest in attending, please email Pip Thorn via pip.thorn@irdepartment.com.au by COB on Friday, 28 March 2025.

The Lumos team looks forward to seeing all those investors who can attend this information session.

Presentation content:

A copy of the presentation will be lodged with the ASX prior to the information session.

-Ends-

This announcement has been approved by the Company Secretary.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact:

Haley Chartres – Australia
H^CK Director
haley@hck.digital
+61 423 139 163

Investor Contact:

Jane Lowe
Managing Director, IR Department
ir@lumosdiagnostics.com
+61 411 117 774

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205, Australia
+61 3 9087 1598

For personal use only